Adjuvant chemotherapy of colon cancer: 3 versus 6 months

BJMO - volume 13, issue 6, october 2019

C. Debeuckelaere MD, L. Triest MD, T. Vandamme MD, B. Van Den Heuvel MD, K. Papadimitriou MD, M. Rasschaert MD, H. Prenen MD, PhD, M. Peeters MD, PhD


For over a decade, oxaliplatin-based adjuvant chemotherapy has been the gold standard for resected early colon cancer. Oxaliplatin is known to cause polyneuropathy, which affects quality of life dramatically. In recent years, there has not been any progress in the development of novel agents to replace oxaliplatin as adjuvant therapy. Consequently, there is a growing interest to investigate whether a shorter course of chemotherapy is sufficient. This article will discuss the history of adjuvant treatment in early-resected colon cancer, the toxicity of oxaliplatin, the results from the IDEA meta-analysis and future prospects.

(BELG J MED ONCOL 2019;13(6):234–239)

Read more

Highlights in gastro-intestinal oncology

BJMO - volume 12, issue 8, december 2018

B. Van Den Heuvel MD, M. Rasschaert MD, L. Triest MD, C. Debeuckelaere MD, F. Couturier , K. Papadimitriou MD, H. Prenen MD, PhD, M. Peeters MD, PhD

Although none of the submitted abstracts in the field of gastro-intestinal oncology reached the presidential sessions of ESMO 2018, some practice-changing and promising data were presented especially in the field of immunotherapy. This report summarises the highlights in the field of colorectal, anal and upper digestive tract cancer.

Read more

P.15 Abiraterone acetate associated rhabdomyolysis

BJMO - 2017, issue 3, february 2017

B. Van Den Heuvel MD, H. Celen , L. Dirix MD, PhD, J. Vandebroeck , A. Rutten MD

Read more